Glaxo flu vaccine sales pegged at $2.1B

As the swine flu gathers pace around the world, analysts forecast windfall orders for GlaxoSmithKline's H1N1 vaccine, which they expect to generate at least $2.1 billion in sales next year. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.